2 hours ago
2
MarketBeat
Sat, March 7, 2026 astatine 7:32 AM CST 6 min read
-
aprevo Technology Platform delivers patient-specific 3D surgical planning, on‑demand 3D‑printed implants and sterile single‑use instruments crossed the pre/intra/post‑op workflow; the institution has expanded into cervical cases and chopped order‑to‑delivery times from astir 8 weeks to six days.
-
Financial outlook: Carlsmed generated $50.5M successful gross successful its archetypal nationalist twelvemonth (Q4 “north of $15M” and a 76.5% gross margin) and guided to $70M–$75.5M for 2025 (≈44% maturation astatine the midpoint) with IPO proceeds providing runway toward cash‑flow breakeven.
-
Clinical and reimbursement advantages: Two‑year information published successful the Global Spine Journal showed a 74% simplification successful revision rates versus accepted banal devices, and the institution has FDA Breakthrough Device designations positive NTAP and imperishable DRG reimbursements that supply important incremental infirmary payments (including an NTAP for cervical procedures reported arsenic “north of $21,000”).
-
Interested successful Carlsmed, Inc.? Here are 5 stocks we similar better.
Carlsmed (NASDAQ:CARL) utilized its presumption astatine Canaccord Genuity’s Musculoskeletal Conference to outline its ngo to amended outcomes and trim the outgo of spine country by lowering reoperation rates successful spine fusion procedures done a personalized, data-driven exertion platform. CEO Mike Cordonnier said the company, founded successful 2018 and recently public, has built a preoperative, intraoperative, and postoperative workflow that combines patient-specific integer surgical readying with build-on-demand implants and post-op information collection.
Cordonnier highlighted Carlsmed’s caller results and guidance, emphasizing accelerated gross maturation and precocious gross margins. He said the institution delivered “north of $15 million” successful fourth-quarter gross and reported a 76.5% gross margin. He besides cited year-on-year maturation of 61% implicit the anterior 4th successful Q4.
→ Uber and Joby Aviation Team Up: Game Changer oregon Hype?
For the afloat year, Cordonnier said Carlsmed generated $50.5 cardinal successful gross successful its archetypal twelvemonth arsenic a nationalist company, representing 86% year-on-year growth. He added that IPO proceeds near the institution with a beardown currency equilibrium and “runway to currency travel interruption even.”
Looking ahead, Cordonnier said the company’s astir caller guidance calls for $70 cardinal to $75.5 cardinal successful gross this year, which helium described arsenic 44% maturation astatine the midpoint.
→ Archer Aviation Stock Tanks—The Real Story Is What Wall Street Overlooked
Cordonnier said aboriginal lawsuit traction has been strong, noting Carlsmed expanded its idiosyncratic basal by astir 70% past twelvemonth and ended the twelvemonth with 253 trained surgeon users. He described the company’s commercialized attack arsenic a hybrid model: a accepted operating-room beingness supported by income agents and distributors, combined with a nonstop squad focused connected lawsuit acquisition, training, and relationship support—particularly successful the preoperative readying phase.
English (CA) · 
English (US) · 
Spanish (MX) ·